Kaisa Helminen
Geschäftsführer bei AIFORIA TECHNOLOGIES OYJ
Vermögen: 599 790 $ am 30.04.2024
Profil
Kaisa Helminen is currently the Chief Operating Officer at Aiforia Technologies Oyj since 2020.
Previously, she worked as a Product Manager at Finnzymes Oy from 2001 to 2011, at Thermo Fisher Scientific Oy from 2011 to 2012, and at Sartorius Biohit Liquid Handling Oy from 2012 to 2014.
Ms. Helminen is a graduate of the University of Helsinki.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
31.08.2023 | 145 700 ( 0,56% ) | 599 790 $ | 30.04.2024 |
Aktive Positionen von Kaisa Helminen
Unternehmen | Position | Beginn |
---|---|---|
AIFORIA TECHNOLOGIES OYJ | Geschäftsführer | 01.07.2020 |
Ehemalige bekannte Positionen von Kaisa Helminen
Unternehmen | Position | Ende |
---|---|---|
Sartorius Biohit Liquid Handling Oy
Sartorius Biohit Liquid Handling Oy Electronic Equipment/InstrumentsElectronic Technology Part of Sartorius AG, Sartorius Biohit Liquid Handling Oy manufactures measuring and controlling devices. The company is based in Helsinki, Finland. | Corporate Officer/Principal | 01.06.2014 |
Thermo Fisher Scientific Oy
Thermo Fisher Scientific Oy Medical SpecialtiesHealth Technology Part of Thermo Fisher Scientific, Inc., Thermo Fisher Scientific Oy is a Finnish company that manufactures and supplies medical and dental instruments. The company is based in Vanda, Finland. The CEO of the company is Timo Tapio Hildén. | Corporate Officer/Principal | 01.05.2012 |
Finnzymes Oy
Finnzymes Oy Pharmaceuticals: MajorHealth Technology The company is part of Thermo Fisher Scientific, the world leader in serving science. Thermo Fisher Scientific enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics. With annual sales of more than $9 billion, Thermo Fisher Scientific has over 30,000 employees and serves more than 350,000 customers in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies as well as environmental, industrial quality and process control settings. Finnzymes, founded in 1986, is a leader in the development of PCR, quantitative real-time PCR, transposon and RNA technologies. Its aim is to develop products which make the difference, products that deliver results not achievable otherwise. | Corporate Officer/Principal | 01.01.2011 |
Ausbildung von Kaisa Helminen
University of Helsinki | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AIFORIA TECHNOLOGIES OYJ | Technology Services |
Private Unternehmen | 3 |
---|---|
Sartorius Biohit Liquid Handling Oy
Sartorius Biohit Liquid Handling Oy Electronic Equipment/InstrumentsElectronic Technology Part of Sartorius AG, Sartorius Biohit Liquid Handling Oy manufactures measuring and controlling devices. The company is based in Helsinki, Finland. | Electronic Technology |
Thermo Fisher Scientific Oy
Thermo Fisher Scientific Oy Medical SpecialtiesHealth Technology Part of Thermo Fisher Scientific, Inc., Thermo Fisher Scientific Oy is a Finnish company that manufactures and supplies medical and dental instruments. The company is based in Vanda, Finland. The CEO of the company is Timo Tapio Hildén. | Health Technology |
Finnzymes Oy
Finnzymes Oy Pharmaceuticals: MajorHealth Technology The company is part of Thermo Fisher Scientific, the world leader in serving science. Thermo Fisher Scientific enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics. With annual sales of more than $9 billion, Thermo Fisher Scientific has over 30,000 employees and serves more than 350,000 customers in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies as well as environmental, industrial quality and process control settings. Finnzymes, founded in 1986, is a leader in the development of PCR, quantitative real-time PCR, transposon and RNA technologies. Its aim is to develop products which make the difference, products that deliver results not achievable otherwise. | Health Technology |